Analysts Set Ascendis Pharma A/S (NASDAQ:ASND) PT at $289.89

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have received an average recommendation of “Moderate Buy” from the nineteen ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, seventeen have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $289.8889.

A number of analysts have recently commented on the company. Bank of America restated a “buy” rating and set a $262.00 price objective on shares of Ascendis Pharma A/S in a report on Thursday, March 5th. Stifel Nicolaus set a $332.00 price objective on Ascendis Pharma A/S in a report on Wednesday, March 4th. Wells Fargo & Company upped their price objective on Ascendis Pharma A/S from $322.00 to $330.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Morgan Stanley restated an “overweight” rating and set a $256.00 price objective on shares of Ascendis Pharma A/S in a report on Thursday, February 12th. Finally, TD Cowen restated a “buy” rating on shares of Ascendis Pharma A/S in a report on Wednesday, January 7th.

Ascendis Pharma A/S Stock Performance

ASND stock opened at $226.69 on Friday. Ascendis Pharma A/S has a 1 year low of $124.06 and a 1 year high of $248.60. The stock’s 50 day moving average price is $227.02 and its 200 day moving average price is $214.20. The firm has a market cap of $14.13 billion, a P/E ratio of -51.52 and a beta of 0.49.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Thursday, February 12th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.58). The business had revenue of $290.38 million during the quarter, compared to the consensus estimate of $285.35 million. On average, research analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Institutional Trading of Ascendis Pharma A/S

Several large investors have recently added to or reduced their stakes in the stock. Advisory Services Network LLC acquired a new stake in shares of Ascendis Pharma A/S during the third quarter valued at about $26,000. Arax Advisory Partners grew its stake in shares of Ascendis Pharma A/S by 212.2% during the fourth quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 104 shares in the last quarter. Leonteq Securities AG acquired a new stake in shares of Ascendis Pharma A/S during the fourth quarter valued at about $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Ascendis Pharma A/S during the fourth quarter valued at about $42,000. Finally, Global Retirement Partners LLC grew its stake in shares of Ascendis Pharma A/S by 111.9% during the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 113 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.